Prognostic significance of B7H4 expression in patients with optimally or maximally cytoreduced ovarian clear cell carcinoma

Aim: Ovarian clear cell carcinoma is known as an aggressive subtype of malignant ovarian neoplasm due to being relatively resistantto platinum based chemotherapy. Therefore, more effective treatment modalities in ovarian clear cell carcinoma are needed. Toinvestigate the association among expression levels of B7H4 with clinicopathological characteristics and also, survival outcomes ofpatients with ovarian clear cell carcinoma.Material and Methods: Formalin-fixed, paraffin-embedded tissue blocks from 31 patients with histologically proven ovarian clearcell carcinoma were eligible for the study. Tissue blocks were immunohistochemically stained with B7H4 antibody and scored forexpression levels of B7H4. The association between expression levels of B7H4 and the clinicopathological characteristics andsurvival outcomes of patients were evaluated.Results: Maximal and optimal cytoreductive surgery rates were 45.2% and 54.8%, respectively. The 5-year disease-free survival andoverall survival rates were 55.6% and 56.6% for the entire cohort, respectively. All tumor specimens had positive immunohistochemicalstaining with B7H4 antibody to some extent. Of the 31 patients, 14 (45.2%) showed high expression and the remaining had low expressionwith B7H4. There was no significant difference between expression levels of B7H4 and clinicopathological characteristics of patients.The 5-year disease-free survival rate was 52.9% in the low expression group and 61.2% in the high expression group. The 5-yearoverall survival rates were comparable between the low expression group and the high expression group (47.2% and 67.5%, p=0.35).Conclusion: IB7H4 expression is a biomarker for ovarian clear cell carcinoma but it is unrelated with clinicopathologic characteristicsand survival outcomes of patients.

PDF

___

1. Cheng C, Qu QX, Shen Y, et al. Overexpression of B7- H4 in tumor infiltrated dendritic cells. J Immunoassay Immunochem 2011;32:353-64.
2. He C, Qiao H, Jiang H, et al. The inhibitory role of b7-h4 in antitumor immunity: association with cancer progression and survival. Clin Dev Immunol 2011;2011:695834.
3. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002;20:29-53.
4. Wang X, Wang T, Xu M, et al. B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas. Hum Immunol 2014;75:1203-9.
5. Kryczek I, Wei S, Zou L, et al. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 2006;177:40-4.
6. Chen C, Qu QX, Shen Y, et al. Induced expression of B7-H4 on the surface of lung cancer cell by the tumorassociated macrophages: a potential mechanism of immune escape. Cancer Lett 2012;317:99-105.
7. Seliger B, Quandt D. The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunol Immunother 2012;61:1327-41.
8. Salceda S, Tang T, Kmet M, et al. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res 2005;306:128-41.
9. Xu M, Zhang B, Zhang M, et al. Clinical relevance of expression of B7-H1 and B7-H4 in ovarian cancer. Oncol Lett 2016;11:2815-9.
10. Pagnotti GM, Atkinson RM, Romeiser J, et al. B7-H4 is Inversely Correlated With T-Cell Infiltration in Clear Cell but Not Serous or Endometrioid Ovarian Cancer. Appl Immunohistochem Mol Morphol 2017;27:515- 22.
11. Maskey N, Li K, Hu M, et al. Impact of neoadjuvant chemotherapy on lymphocytes and co-inhibitory B7- H4 molecule in gastric cancer: low B7-H4 expression associates with favorable prognosis. Tumour Biol 2014;35:11837-43.
12. Xu Y, Zhu S, Song M, et al. B7-H4 expression and its role in interleukin-2/interferon treatment of clear cell renal cell carcinoma. Oncol Lett 2014;7:1474-8.
13. Liang L, Jiang Y, Chen JS, et al. B7-H4 expression in ovarian serous carcinoma: a study of 306 cases. Hum Pathol 2016;57:1-6.
14. Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, et al. B7-H4 overexpression in ovarian tumors. Gynecol Oncol 2006;100:44-52.
15. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-9.
16. Kurman RJ, Carcangiu, ML, Herrington CS, et al. WHO Classification of Tumours of Female Reproductive Organs. Fourth Edition. Lyon. IARC 2014;Chapter 1: Tumors of the ovary.
17. Prat J, Belhadj H, Berek J, et al. Abridged republication of FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum. Eur J Gynaecol Oncol 2015;36:367-9.
18. Pan K, Gong J, Huynh K, et al. Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies. Target Oncol 2019.
19. Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study. Ann Oncol 2019.
20. Meng Z, Wang F, Zhang Y, et al. B7-H4 as an independent prognostic indicator of cancer patients: a meta-analysis. Oncotarget 2017;8:68825-36.